Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC-PTLD Trial
PACTR202407655325739Phase 3Not yet recruiting
- Sponsor
- Aurum Institute
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised trial of acetylcysteine in Tuberculosis (TB) (4 arms), sponsored by Aurum Institute. Primary endpoint: FEV1% of predicted at month 12. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
acetylcysteine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202407655325739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202407655325739.